The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-18S4
Application #
9690676
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
18
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Yates, Luke A; Aramayo, Ricardo J; Pokhrel, Nilisha et al. (2018) A structural and dynamic model for the assembly of Replication Protein A on single-stranded DNA. Nat Commun 9:5447
Lynch, Thomas J; Anderson, Preston J; Rotti, Pavana G et al. (2018) Submucosal Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse Tracheal Epithelium. Cell Stem Cell 22:653-667.e5
Albright, Emily L; Schroeder, Mary C; Foster, Kendra et al. (2018) Nipple-Sparing Mastectomy is Not Associated with a Delay of Adjuvant Treatment. Ann Surg Oncol 25:1928-1935
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Link, Brian K (2018) Transformation of follicular lymphoma - Why does it happen and can it be prevented? Best Pract Res Clin Haematol 31:49-56
Guy, Christopher L; Weiss, Elisabeth; Christensen, Gary E et al. (2018) CALIPER: A deformable image registration algorithm for large geometric changes during radiotherapy for locally advanced non-small cell lung cancer. Med Phys 45:2498-2508
Scott, Aaron T; Howe, James R (2018) Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract 14:471-482
Pelletier, Daniel J; Czeczok, Thomas W; Bellizzi, Andrew M (2018) A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma. Histopathology 73:162-166
Brooks, John M; Chapman, Cole G; Schroeder, Mary C (2018) Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome. Appl Health Econ Health Policy 16:381-393
Li, Fengyin; Zeng, Zhouhao; Xing, Shaojun et al. (2018) Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf. Nat Commun 9:5452

Showing the most recent 10 out of 1080 publications